Metabolic Syndrome and Rheumatic Diseases in Chad: Prevalence, Associated Factors and Clinical Impact

  • Harine Abdel Aziz Garba Department of Rheumatology, Chad Refoundation Hospital (HRT), University of N'Djamena, Chad
  • Ramadhane Bouchrane Rheumatology Unit, National Center for Orthopedic Devices (CNAO), Dakar, Senegal
  • Adama Bah Department of Rheumatology, Ignace Deen University Hospital, Gamal Abdel Nasser University of Conakry, Guinea
  • Djikoldinguem Marschall Mouandilmadji Department of Endocrinology and Diabetology, University Hospital of N'Djamena, Chad
  • Harine Abdel Aziz Hamid Department of Rheumatology, Chad Refoundation Hospital (HRT), Chad
  • Moustapha Niasse Department of Rheumatology, Coud Hospital, Cheikh Anta Diop University of Dakar, Senegal
  • Saidou Diallo Department of Rheumatology, Coud Hospital, Cheikh Anta Diop University of Dakar, Senegal
Keywords: Chad; metabolic syndrome; rheumatic diseases; comorbidities; quality of life; Sub-Saharan Africa

Abstract

Objective: To assess the prevalence of metabolic syndrome (MS) and its clinical impact among patients with rheumatic diseases in Chad.
Methods: A retrospective, cross-sectional, analytical study was conducted at the (HRT) Rheumatology Department from January 2018 to May 2024. Among 5000 patients, 330 fulfilled IDF and 214 WHO criteria for MS. Clinical, laboratory, and therapeutic data, as well as functional scores (SF-36, DAS28, BASFI, WOMAC), were systematically analyzed.
Results: MS prevalence was 6.6% (IDF) and 4.3% (WHO). The cohort was predominantly female (88.7%), with a mean age of 49.8 ± 12.4 years. The most frequent components were abdominal obesity (93.0%), hypertension (89.7%), and hyperglycemia (64.8%). Associated diseases included connective tissue disorders (40.9%), degenerative conditions (34.3%), and autoinflammatory diseases (24.8%). After a mean two-year follow-up, functional and quality-of-life scores improved, although 13 patients developed cardio-renal complications. Conclusions: MS is common among rheumatology patients in Chad and worsens disease prognosis. Systematic screening and multidisciplinary management are essential to improve outcomes and quality of life.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

1. Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., … Smith, S. C., Jr. (2009). Harmonizing the metabolic syndrome: A joint interim statement of the IDF, NHLBI, AHA, and others. Circulation, 120(16), 1640–1645. https://doi.org/10.1161/CIRCULATIONAHA.109.192644
2. Crowson, C. S., Myasoedova, E., Davis, J. M., Matteson, E. L., Roger, V. L., Therneau, T. M., … Gabriel, S. E. (2013). Increased prevalence of metabolic syndrome associated with rheumatoid arthritis in patients without clinical cardiovascular disease. Journal of Rheumatology, 40(11), 1795–1802. https://doi.org/10.3899/jrheum.130197
3. González-Gay, M. A., & González-Juanatey, C. (2017). Inflammation, metabolic syndrome and cardiovascular risk in rheumatoid arthritis: Linking mechanisms to clinical practice. Rheumatology, 56(1), 7–19. https://doi.org/10.1093/rheumatology/kew378
4. Motala, A. A., Esterhuizen, T., Pirie, F. J., & Omar, M. A. K. (2011). The prevalence of metabolic syndrome and determination of the optimal waist circumference cutoff points in a rural South African community. Diabetes Care, 34(4), 1032–1037. https://doi.org/10.2337/dc10-1921
5. Peters, M. J., van Halm, V. P., Voskuyl, A. E., Lems, W. F., Smulders, Y. M., Visser, M., … Nurmohamed, M. T. (2009). Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis & Rheumatism, 61(11), 1571–1579. https://doi.org/10.1002/art.24836
6. Toms, T. E., Panoulas, V. F., John, H., Douglas, K. M. J., & Kitas, G. D. (2012). Metabolic syndrome in rheumatoid arthritis: Association with disease activity, duration and cardiovascular risk factors. Annals of the Rheumatic Diseases, 71(9), 1506–1512. https://doi.org/10.1136/annrheumdis-2011-201280
7. Savadogo, B., Zabsonré/Tiendrébéogo, W. J. S., Kaboré, F., Nzigou, N., Abassiri, K. A. E., Nonguierma, V., Ouédraogo, A., & Ouédraogo, D. D. (2022). Prévalence du syndrome métabolique en consultation rhumatologie en Afrique subsaharienne. Rhumatologie Africaine Francophone, 3(2), 1–5. https://doi.org/10.62455/raf.v3i2.33
8. Abandazegoué-Andjembé, L. C., Khadiri, A., Diallo, S., Niasse, M., Alkassan, Y., Diouf, C., Diaw, C. A. B., Guèye, Y. A. N., & Bouchrane, R. (2023, 8–10 mars). Syndrome métabolique et pathologies rhumatologiques : étude de 373 observations au Sénégal (CO06). Dans Livre du programme et des résumés, Congrès STR/SARh, Lomé, Togo. Rhumatologie Africaine Francophone, 5(2), p. 21.
9. Nouvedji, K. A., Diallo, M. L., Lokou, P., Gbedey, G., Tiadjéri, M., Koffi-Tessio, V. E. S., Tagbor, C., Dzono-Assoumou, J. G., Fianyo, E., Kakpovi, K., Houzou, P., Oniankitan, O., & Mijiyawa, M. (2023, 8–10 mars). Syndrome métabolique et affections rhumatismales à Kara (CO07). Dans Livre du programme et des résumés, Congrès STR/SARh, Lomé, Togo. Rhumatologie Africaine Francophone, 5(2), pp. 21–22.
10. Zomalheto, Z., Gounongbe, M., & Dossou-Yovo, H. (2017). Influence of metabolic syndrome in low back pain in Benin people. Open Journal of Rheumatology and Autoimmune Diseases, 7(3), 153–157. https://doi.org/10.4236/ojra.2017.73015
11. Alkassan, Y. (2019). Syndrome métabolique et pathologies rhumatismales : étude de 330 observations (Mémoire de médecine, Université Cheikh Anta Diop). Bibliothèque numérique UCAD, cote memm_2019_0658.
12. Toms TE, Panoulas VF, Douglas KMJ, Griffiths HR, Kitas GD. Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60 - a cross-sectional study. Arthritis Res Ther. 2009;11(5):R110. doi:10.1186/ar2765
13. Grzechnik K, Targońska-Stępniak B. Metabolic syndrome and rheumatoid arthritis activity. Nutrients. 2023;15(8):1825. doi:10.3390/nu15081825
14. Özmen M, Yersal Ö, Öztürk S, Ataman Ş. Prevalence of the metabolic syndrome in rheumatoid arthritis. Eur J Rheumatol. 2014;1(1):1–4. doi:10.5152/eurjrheum.2014.001
15. Šalamon L, Morović-Vergles J, Marasović-Krstulović D, et al. Differences in the prevalence and characteristics of metabolic syndrome in rheumatoid arthritis and osteoarthritis: A multicentric study. Rheumatol Int. 2015;35:2047–57. doi:10.1007/s00296-015-3307-0
16. Luo P, Xu W, Ye D, et al. Metabolic syndrome is associated with an increased risk of rheumatoid arthritis: A prospective cohort study including 369,065 participants (UK Biobank). J Rheumatol. 2024;51(4):360–7. doi:10.3899/jrheum.2023-0349
17. Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, Shintani A, Stein CM. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis. 2008;196(2):756–63. doi:10.1016/j.atherosclerosis.2007.01.004
18. Dao HH, Do QT, Sakamoto J. Increased frequency of metabolic syndrome among Vietnamese women with early rheumatoid arthritis: A cross-sectional study. Arthritis Res Ther. 2010;12(6):R218. doi:10.1186/ar3203
19. Pandey PK, Misra R, Agarwal V. Prevalence of metabolic syndrome in treatment-naïve rheumatoid arthritis patients. Arch Rheumatol. 2017;32(4):317–24. doi:10.5606/ArchRheumatol.2017.6318
20. Hee JY, Tan YZ, Fong W-W, et al. Metabolic syndrome and its effect on the outcomes of rheumatoid arthritis: A multi-ethnic cohort in Singapore. Int J Rheum Dis. 2022;25(8):935–42. doi:10.1111/1756-185X.14338
21. Apostolopoulos D, Vincent F, Hoi A, Morand E. Associations of metabolic syndrome in systemic lupus erythematosus. Lupus Sci Med. 2020;7(1):e000436. doi:10.1136/lupus-2020-000436
22. Loganathan A, Kamalaraj N, El-Haddad C, Pile K. Systematic review and meta-analysis on prevalence of metabolic syndrome in psoriatic arthritis, rheumatoid arthritis and psoriasis. Int J Rheum Dis. 2021;24(9):1112–20. doi:10.1111/1756-185X.14147
23. Abourazzak FE, Mansouri S, Najdi A, et al. Prevalence of metabolic syndrome in patients with rheumatoid arthritis in Morocco: A cross-sectional study of 179 cases. Clin Rheumatol. 2014;33(11):1549–55. doi:10.1007/s10067-014-2570-x
24. Eldin AB, ElBakry SA, Morad CS, Aly MH. The impact of metabolic syndrome on rheumatoid arthritis in a cohort of Egyptian patients. Egypt Rheumatol. 2018;40(1):7–10. doi:10.1016/j.ejr.2017.09.005
25. Tekaya R, Rouached L, Ben Ahmed H, et al. Prevalence of metabolic syndrome in rheumatoid arthritis and association with disease outcomes: A Tunisian study. Indian J Rheumatol. 2022;17(4):359–63. doi:10.4103/injr.injr_122_21
26. Cai W, Tang X, Pang M. Prevalence of metabolic syndrome in patients with rheumatoid arthritis: An updated systematic review and meta-analysis. Front Med. 2022;9:855141. doi:10.3389/fmed.2022.855141
27. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Costa F. Diagnosis and management of the metabolic syndrome: An AHA/NHLBI scientific statement. Circulation. 2005;112(17):e285–90. doi:10.1161/CIRCULATIONAHA.105.169404
Published
2025-09-07
How to Cite
Garba, H. A. A., Bouchrane, R., Bah, A., Mouandilmadji, D. M., Hamid, H. A. A., Niasse, M., & Diallo, S. (2025). Metabolic Syndrome and Rheumatic Diseases in Chad: Prevalence, Associated Factors and Clinical Impact. European Scientific Journal, ESJ, 45, 92. Retrieved from https://eujournal.org/index.php/esj/article/view/19999
Issue
Vol 45 (2025): ESI Preprints
Section
ESI Preprints

Copyright (c) 2025 Harine Abdel Aziz Garba, Ramadhane Bouchrane, Adama Bah, Djikoldinguem Marschall Mouandilmadji, Harine Abdel Aziz Hamid, Moustapha Niasse, Saidou Diallo

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.